| Date | Title | Description |
| 27.09.2024 | Ascidian Therapeutics Named to 2024 "Endpoints 11" List of Most Promising Biotechs | BOSTON, September 27, 2024 – Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced that it has been named as one of the Endpoints 11 most promising biotech companies of 2024. This a... |
| 18.06.2024 | Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases | Ascidian to receive $42 million in initial payment, and up to $1.8 billion in research, clinical and commercial milestone payments, as well as commercial royalties
Per-target agreement enables Ascidian to pursue additional internal and coll... |
| 08.11.2023 | Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO | Funds from ATP will support the progress of Ascidian’s lead program in ABCA4 retinopathies, including Stargardt disease, and advance key pipeline programs
in CNS and neuromuscular diseases |
| 08.11.2023 | Ascidian Therapeutics Scores $40M in Series A Extension |
BOSTON, MA, Ascidian Therapeutics, a biotechnology company, announced $40 million in Series A extension funding committed by Apple Tree Partners.
>> Click here for more funding data on Ascidian Therapeutics
>> To export Asci... |
| 08.11.2023 | Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO | Funds from ATP will support the progress of Ascidian’s lead program in ABCA4 retinopathies, including Stargardt disease, and advance key pipeline programs
in CNS and neuromuscular diseases
Ascidian anticipates filing an IND and initiating... |
| 08.11.2023 | Ascidian Therapeutics Raises $40M in Series A Extension Financing | Ascidian Therapeutics, a Boston, MA-based biotechnology company focused on treating human diseases by rewriting RNA, raised $40m in Series A extension funding.
The funds were committed by Apple Tree Partners.
The company intends to use the ... |
| 13.10.2022 | Ascidian Therapeutics Raises $50M in Series A Funding | Ascidian Therapeutics, a Boston, MA-based biotechnology company, raised $50M in Series A funding.
The round was led by ATP.
The company intends to use the funds to expand its development efforts to extend the therapeutic potential of RNA me... |
| 12.10.2022 | Ascidian Therapeutics Launches to Rewrite RNA | ATP incubated and built Ascidian with $50 million in Series A funding |
| 12.10.2022 | Ascidian Therapeutics Launches to Rewrite RNA | ATP incubated and built Ascidian with $50 million in Series A funding
Pioneering RNA exon editing platform expands therapeutic possibilities to treat diseases not addressed by today’s gene editing technologies
Lead program targeting ABCA4... |
| - | Ascidian Therapeutics | “Ascidian is redefining the treatment of disease by rewriting RNA.” |
